Industry Growth Insights published a new data on “Biological API Drug Manufacturing Market”. The research report is titled “Biological API Drug Manufacturing Market research by Types (In-House manufacturing, Contract manufacturing, , API contract manufacturing dominates the global biological API drug manufacturing market.), By Applications (Monoclonal Antibody (mAb) Therapies, Vaccines, Insulin Therapies, Interferon Therapies, Other), By Players/Companies Lonza, Boehringer Ingelheim BioXcellence, Celltrion, DSM, Samsung BioLogics, Fujifilm Diosynth Biotechnologies, Cytovance Biologics, AbbVie, Baxter, CEPiA Sanofi, GSK, Pfizer CentreOne, Sandoz, Vetter, Wuxi Biologics”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Biological API Drug Manufacturing Market Research Report
By Type
In-House manufacturing, Contract manufacturing, , API contract manufacturing dominates the global biological API drug manufacturing market.
By Application
Monoclonal Antibody (mAb) Therapies, Vaccines, Insulin Therapies, Interferon Therapies, Other
By Companies
Lonza, Boehringer Ingelheim BioXcellence, Celltrion, DSM, Samsung BioLogics, Fujifilm Diosynth Biotechnologies, Cytovance Biologics, AbbVie, Baxter, CEPiA Sanofi, GSK, Pfizer CentreOne, Sandoz, Vetter, Wuxi Biologics
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
234
Number of Tables & Figures
164
Customization Available
Yes, the report can be customized as per your need.
Global Biological API Drug Manufacturing Market Report Segments:
The global Biological API Drug Manufacturing market is segmented on the basis of:
Types
In-House manufacturing, Contract manufacturing, , API contract manufacturing dominates the global biological API drug manufacturing market.
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Monoclonal Antibody (mAb) Therapies, Vaccines, Insulin Therapies, Interferon Therapies, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Lonza
- Boehringer Ingelheim BioXcellence
- Celltrion
- DSM
- Samsung BioLogics
- Fujifilm Diosynth Biotechnologies
- Cytovance Biologics
- AbbVie
- Baxter
- CEPiA Sanofi
- GSK
- Pfizer CentreOne
- Sandoz
- Vetter
- Wuxi Biologics
Highlights of The Biological API Drug Manufacturing Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- In-House manufacturing
- Contract manufacturing
- API contract manufacturing dominates the global biological API drug manufacturing market.
- By Application:
- Monoclonal Antibody (mAb) Therapies
- Vaccines
- Insulin Therapies
- Interferon Therapies
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Biological API Drug Manufacturing Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Biological API drug manufacturing is the process of creating drugs using living organisms as a source of ingredients. This method is often more expensive and time-consuming than traditional drug production methods, but it can offer unique benefits such as increased safety and specificity.
Some of the major players in the biological api drug manufacturing market are Lonza, Boehringer Ingelheim BioXcellence, Celltrion, DSM, Samsung BioLogics, Fujifilm Diosynth Biotechnologies, Cytovance Biologics, AbbVie, Baxter, CEPiA Sanofi, GSK, Pfizer CentreOne, Sandoz, Vetter, Wuxi Biologics.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Biological API Drug Manufacturing Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Biological API Drug Manufacturing Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Biological API Drug Manufacturing Market - Supply Chain
4.5. Global Biological API Drug Manufacturing Market Forecast
4.5.1. Biological API Drug Manufacturing Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Biological API Drug Manufacturing Market Size (000 Units) and Y-o-Y Growth
4.5.3. Biological API Drug Manufacturing Market Absolute $ Opportunity
5. Global Biological API Drug Manufacturing Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Biological API Drug Manufacturing Market Size and Volume Forecast by Type
5.3.1. In-House manufacturing
5.3.2. Contract manufacturing
5.3.4. API contract manufacturing dominates the global biological API drug manufacturing market.
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Biological API Drug Manufacturing Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Biological API Drug Manufacturing Market Size and Volume Forecast by Application
6.3.1. Monoclonal Antibody (mAb) Therapies
6.3.2. Vaccines
6.3.3. Insulin Therapies
6.3.4. Interferon Therapies
6.3.5. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Biological API Drug Manufacturing Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Biological API Drug Manufacturing Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Biological API Drug Manufacturing Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Biological API Drug Manufacturing Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Biological API Drug Manufacturing Demand Share Forecast, 2019-2026
9. North America Biological API Drug Manufacturing Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Biological API Drug Manufacturing Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Biological API Drug Manufacturing Market Size and Volume Forecast by Application
9.4.1. Monoclonal Antibody (mAb) Therapies
9.4.2. Vaccines
9.4.3. Insulin Therapies
9.4.4. Interferon Therapies
9.4.5. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Biological API Drug Manufacturing Market Size and Volume Forecast by Type
9.7.1. In-House manufacturing
9.7.2. Contract manufacturing
9.7.4. API contract manufacturing dominates the global biological API drug manufacturing market.
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Biological API Drug Manufacturing Demand Share Forecast, 2019-2026
10. Latin America Biological API Drug Manufacturing Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Biological API Drug Manufacturing Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Biological API Drug Manufacturing Market Size and Volume Forecast by Application
10.4.1. Monoclonal Antibody (mAb) Therapies
10.4.2. Vaccines
10.4.3. Insulin Therapies
10.4.4. Interferon Therapies
10.4.5. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Biological API Drug Manufacturing Market Size and Volume Forecast by Type
10.7.1. In-House manufacturing
10.7.2. Contract manufacturing
10.7.4. API contract manufacturing dominates the global biological API drug manufacturing market.
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Biological API Drug Manufacturing Demand Share Forecast, 2019-2026
11. Europe Biological API Drug Manufacturing Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Biological API Drug Manufacturing Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Biological API Drug Manufacturing Market Size and Volume Forecast by Application
11.4.1. Monoclonal Antibody (mAb) Therapies
11.4.2. Vaccines
11.4.3. Insulin Therapies
11.4.4. Interferon Therapies
11.4.5. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Biological API Drug Manufacturing Market Size and Volume Forecast by Type
11.7.1. In-House manufacturing
11.7.2. Contract manufacturing
11.7.4. API contract manufacturing dominates the global biological API drug manufacturing market.
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Biological API Drug Manufacturing Demand Share, 2019-2026
12. Asia Pacific Biological API Drug Manufacturing Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Biological API Drug Manufacturing Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Biological API Drug Manufacturing Market Size and Volume Forecast by Application
12.4.1. Monoclonal Antibody (mAb) Therapies
12.4.2. Vaccines
12.4.3. Insulin Therapies
12.4.4. Interferon Therapies
12.4.5. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Biological API Drug Manufacturing Market Size and Volume Forecast by Type
12.7.1. In-House manufacturing
12.7.2. Contract manufacturing
12.7.4. API contract manufacturing dominates the global biological API drug manufacturing market.
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Biological API Drug Manufacturing Demand Share, 2019-2026
13. Middle East & Africa Biological API Drug Manufacturing Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Biological API Drug Manufacturing Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Biological API Drug Manufacturing Market Size and Volume Forecast by Application
13.4.1. Monoclonal Antibody (mAb) Therapies
13.4.2. Vaccines
13.4.3. Insulin Therapies
13.4.4. Interferon Therapies
13.4.5. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Biological API Drug Manufacturing Market Size and Volume Forecast by Type
13.7.1. In-House manufacturing
13.7.2. Contract manufacturing
13.7.4. API contract manufacturing dominates the global biological API drug manufacturing market.
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Biological API Drug Manufacturing Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Biological API Drug Manufacturing Market: Market Share Analysis
14.2. Biological API Drug Manufacturing Distributors and Customers
14.3. Biological API Drug Manufacturing Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Lonza
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Boehringer Ingelheim BioXcellence
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Celltrion
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. DSM
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Samsung BioLogics
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Fujifilm Diosynth Biotechnologies
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Cytovance Biologics
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. AbbVie
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Baxter
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. CEPiA Sanofi
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. GSK
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Pfizer CentreOne
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Sandoz
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Vetter
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. Wuxi Biologics
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
